La chaîne d'options affiche les données clés des options sur actions de Ncino à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Ncino..

Ncino (NASDAQ:NCNO) Stock, Chaîne d'Options

Ncino

Ncino Inc is a provider of cloud-based software for financial institutions. Its software solution digitizes, automates, and streamlines inefficient and complex processes & workflow and utilizes data analytics & artificial intelligence that enables financial institutions to onboard new clients, make loans and manage the entire loan life cycle, open deposits, and other accounts and manage regulatory compliance. It also offers professional services, including configuration & implementation, training, and advisory services. Ncino generates the majority of its revenue from subscription services. The company caters to financial institutions, enterprise banks, regional banks, community banks, and credit unions. The vast majority of its revenue comes from the United States.

Ncino Inc

News

BFRI

Biofrontera Reaches Milestone With 100 RhodoLED XL Lamps Installed In US Market Since June 2024 Launch; Approved For PDT Treatment Of Actinic Keratoses On Face And Scalp

Qualcomm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) shares settled higher <a href="https://www.benzinga.com/24/12/42633922/qualcomm-bags-win-in-chips-licensing-trial-against-arm-but-the-battle-is-not-over-yet">during Friday's session</a>.
Qualcomm bagged <a href="https://www.benzinga.com/24/12/42646386/qualcomm-scores-big-in-arm-lawsuit-will-bearish-trends-back-down">a key win in its legal battle</a> against semiconductor design company Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>). A federal jury in Delaware ruled that Qualcomm did not violate its licensing agreement with Arm, clearing a hurdle for the San Diego, California headquartered chipmaker.
With the recent buzz around Qualcomm, some investors may be eyeing potential gains from the company's dividends, too. As of now, Qualcomm offers an annual dividend yield of 2.22%, which is a quarterly dividend amount of 85 cents per share ($3.40 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
See Also: <a href="https://www.benzinga.com/24/12/42647238/retail-investors-driving-change-platforms-rethink-engagement-strategies">Can Trading Be Like &#8216;Fantasy Sports&#8217;? BullRush CEO Addresses How Platforms Adapt To Change</a>
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $269,851 or around 1,765 shares. For a more modest $100 per month or $1,200 per year, you would need $53,970 or around 353 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($3.40 in this case). So, $6,000 / $3.40 = 1,765 ($500 per month), and $1,200 / $3.40 = 353 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
QCOM Price Action: Shares of Qualcomm gained 1.7% to close at $152.89 on Friday. The company&#8217;s stock gained another 1.9% in after-hours trading.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Trading Ideas

QCOM

How To Earn $500 A Month From Qualcomm Stock

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 12.91% on an annualized basis producing an average annual return of 23.94%. Currently, Veeva Systems has a market capitalization of $36.44 billion. 
Buying $100 In VEEV: If an investor had bought $100 of VEEV stock 10 years ago, it would be worth $837.57 today based on a price of $224.43 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734964211_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VEEV

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

COSM

Cosmos Health CEO Greg Siokas And CFO George Terzis Increase Stake By 343,122 Shares Valued At $200K

Loop Capital analyst Mark Schappel maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Buy and lowers the price target from $310 to $300.

Price Target

Analyst Ratings

MNDY

Loop Capital Maintains Buy on Monday.Com, Lowers Price Target to $300

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $120 price target.

Reiteration

CYTK

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

<a href="https://www.bseindia.com/xml-data/corpfiling/AttachLive/79ff5f5f-81a0-4bb0-a2f0-b93541f1164e.pdf" title="https://www.bseindia.com/xml-data/corpfiling/AttachLive/79ff5f5f-81a0-4bb0-a2f0-b93541f1164e.pdf">https://www.bseindia.com/xml-data/corpfiling/AttachLive/79ff5f5f-81a0-4bb0-a2f0-b93541f1164e.pdf</a>

Global

Dr. Reddy's Laboratories Forms New Subsidiary In Finland, 'Dr. Reddy's Finland Oy', As Step-Down Wholly-Owned Entity

6th National Domestic Violence Project in Europe Strengthens SuperCom's Position as a Leader in the Space
TEL AVIV, Israel, Dec. 23, 2024 /PRNewswire/ -- SuperCom (NASDAQ:&nbsp;SPCB),&nbsp;a global provider of secure solutions for the e-Government, IoT, and Cybersecurity sectors, announced today the successful launch of its new electronic monitoring (EM) project in Latvia. Following a competitive tender process, SuperCom was awarded this project, marking its third national contract in Latvia and further expanding its role in supporting the country's public safety efforts with the inclusion of domestic violence prevention.
Under this program, SuperCom is deploying its advanced PureSecurity EM Suite, featuring GPS tracking devices, secure communications, and real-time monitoring capabilities. SuperCom's technology will enhance the State Police of Latvia's ability to oversee offenders, enabling more effective prevention and response to domestic violence cases while bolstering regional public safety and security.

Contracts

SPCB

SuperCom Awarded New Domestic Violence Monitoring Project Using It's PureSecurity EM Suite, With The State Police Of Latvia

Benchmark analyst Bruce Jackson maintains Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) with a Buy and raises the price target from $15 to $17.

HUMA

Benchmark Maintains Buy on Humacyte, Raises Price Target to $17

Despegar.com, Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) shares are surging premarket on Monday after the company disclosed a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42643653/despegar-com-enters-into-merger-agreement-to-be-acquired-by-prosus-for-19-50-per-share-in-cash" rel="noreferrer noopener">deal to be acquired</a> by Prosus for $19.50 per share in an all-cash transaction.
The transaction price reflects a 34% premium over Despegar&#8217;s 90-day volume-weighted average share price as of December 20, 2024.
Despegar&#8217;s Board of Directors has approved the merger agreement and recommended shareholder approval following the unanimous endorsement of a Transaction Committee composed of independent directors.
The deal values Despegar at approximately $1.7 billion in enterprise value.
Despegar will gain access to Prosus&#8217; extensive resources, operational expertise, and advanced AI capabilities.
As per the deal, a wholly owned subsidiary of Prosus will merge with Despegar, with Despegar remaining as the surviving entity.
Each outstanding share of Despegar will be converted into the right to receive $19.50 in cash, while the company&#8217;s Series A Preferred Shares will be canceled and converted into payments as specified by their terms.
The transaction is anticipated to close in the second quarter of 2025, pending shareholder approval, regulatory clearances, and other <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42643979/prosus-to-acquire-latin-americas-leading-online-travel-agency-despegar-for-us-1-7bn" rel="noreferrer noopener">customary closing conditions</a>.
Following the transaction&#8217;s completion, Despegar will transition to a privately held company. Its ordinary shares will be delisted from the New York Stock Exchange and will no longer trade on any public market.
Damian Scokin, Despegar&#8217;s CEO said, &#8221;Our customers will benefit from access to more services, enhanced customer experiences, increased loyalty benefits, and more comprehensive solutions tailored to their needs. Together we are setting the stage for a new era of travel marked by greater connectivity, innovation and value.&#8221;
Fabricio Bloisi, CEO of Prosus Group, added, &#8220;Despegar adds significantly to our strong ecosystem in Latin America, a market with amazing growth potential. Today&#8217;s announcement is about opportunity and growth &#8211; alone Despegar is a successful business with great fundamentals and a motivated management team; together, both Despegar and Prosus will make it even stronger.&#8221;
Investors can gain exposure to the DESP via Amplify ETF Trust Amplify Travel Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWAY#NYSE">AWAY</a>) and Global X MSCI Argentina ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARGT#NYSE">ARGT</a>).
Price Action: DESP shares are up 32.80% at $19.45 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42643303" target="_blank" rel="noreferrer noopener">US Stocks To Open Higher As Wall Street Expects &#8216;Santa Rally&#8217; In Shortened Trading Week: MicroStrategy, Palantir, Qualcomm Among Stocks In Focus</a></li>
</ul>
Photo by Capri23auto from Pixabay

Equities

Mid Cap

Movers

ARGT

AWAY

DESP

Despegar To Be Acquired By Prosus For $1.7 Billion in All Cash Deal

<ul>
<li>TLRY</li>
<li>TSLA</li>
<li>AMD</li>
<li>NVDA</li>
<li>LUNR</li>
<li>PLTR</li>
<li>CORN</li>
<li>MSTR</li>
<li>KULR</li>
<li>QQQ</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

CORN

KULR

LUNR

MSTR

NVDA

PLTR

TLRY

TSLA

Top 10 Trending Stocks On WallStreetBets As Of December 23, 2024 (Via Swaggy Stocks)

On December 23, 2024, ReNew Energy Global Plc ("ReNew") announced the signing of definitive agreement to sell ReNew Sun Waves Private Limited ("RSWPL"), which houses a 300 MW operating solar asset to Anzen India Energy Yield Plus Trust ("Anzen"). The transaction is expected to close post completion of contractual obligations and conditions precedent including receipt of lender approval. Under the agreement, ReNew Private Limited, parent of RSWPL, will sell 100% shareholding and economic interest in RSWPL. The enterprise value determined under the agreement is ~$176 million&#x2A;, subject to net current assets and other such adjustments as provided in the definitive documents. Additionally, ~$17 million&#x2A; is expected to be received as an earn-out on account of change in law proceeds pertaining to increase in basic customs duty (BCD), safeguard duty (SGD) and goods &amp; service tax (GST), after the first payment is realised by RSWPL. The 300 MW SECI solar project is located in Jaisalmer, Rajasthan, and has been operational for ~3 years. The tariff for the 25-year power purchase agreement is INR 2.55/unit.

Asset Sales

ReNew Energy Global Announced Sale Of ReNew Sun Waves' 300 MW Solar Asset To Anzen India Energy Yield Plus For ~$176M; ~$17M Earn-Out Expected; The Tariff For The 25-Year Power Purchase Agreement Is INR 2.55/Unit

Benchmark analyst Michael Albanese reiterates Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) with a Buy and maintains $70 price target.

Benchmark Reiterates Buy on Winnebago Industries, Maintains $70 Price Target

Offerings

MGOL

MGO Global Prices Upsized $6M Public Offering Of 6.32M Units At $0.95 Per Unit; Includes Common Stock And Warrants Exercisable At $1.425 Pending Stockholder Approval; Closing Expected December 24, 2024

--Multi-year Agreement with ADT for Several Servicing Needs--
Spruce Power Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) ("Spruce" or the "Company") today announced the first customer for its Spruce Pro servicing business. Spruce signed a multi-year Service Agreement with ADT, under which Spruce Pro will facilitate the management and resolution of workmanship and equipment warranty claims for customers of ADT's former solar business, which it wound down earlier in 2024.

Spruce Power Holding Corporation Class A Common Stock

SPRU

Spruce Power Announces Multi-Year Agreement With ADT For Several Servicing Needs Of ADT's Former Solar Business

Battle lines are drawn in <a href="https://www.benzinga.com/topic/defense">the defense sector</a>. On one side, Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) riding high on a meteoric stock surge of over 350% this year. On the other, defense titan Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), grappling with sluggish stock performance and stiff competition from a rising tech consortium.
<h2 class="wp-block-heading">The Disruptor: Palantir</h2>
Palantir, alongside Anduril Industries, is leading <a href="https://www.benzinga.com//node/42640010">a groundbreaking coalition</a> with Elon Musk&#8216;s SpaceX and OpenAI to revolutionize the $850 billion U.S. defense market. The goal? Outpace traditional contractors by integrating AI-powered solutions and autonomous systems. 
Palantir's AI Platform already works seamlessly with Anduril&#8217;s Lattice software, signaling a shift toward modern, agile defense technologies.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064119/Screenshot-2024-12-23-at-5.04.06-PM.png" alt="" class="wp-image-703970" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064119/Screenshot-2024-12-23-at-5.04.06-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064119/Screenshot-2024-12-23-at-5.04.06-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically, PLTR stock is on a tear. Its share price of $80.55 is comfortably above the eight, 20 and 50-day simple moving averages (SMAs), signaling strong bullish momentum. However, with a relative strength index (RSI) of 70.81, it's entering overbought territory—a red flag for cautious investors.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/24/12/42620067/palantir-defies-gravity-army-deal-nasdaq-100-spotlight-fuel-rally">Palantir Defies Gravity: Army Deal, Nasdaq 100 Spotlight Fuel Rally</a>
<h2 class="wp-block-heading">The Titan: Lockheed Martin</h2>
Meanwhile, Lockheed is feeling the heat. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064219/Screenshot-2024-12-23-at-5.04.17-PM.png" alt="" class="wp-image-703971" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064219/Screenshot-2024-12-23-at-5.04.17-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064219/Screenshot-2024-12-23-at-5.04.17-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
The defense giant's stock, at $489.02, is below key moving averages, including its 200-day SMA of $510.22, indicating bearish sentiment. A relative strength index (RSI) of 29.59 suggests the stock is oversold, leaving a sliver of hope for a bounce-back.
Despite its legacy status and deep-rooted Pentagon ties, Lockheed faces mounting pressure to adapt as rivals like Palantir challenge its dominance with innovative, cost-efficient technologies.
<h2 class="wp-block-heading">The Verdict</h2>
Palantir's agility and tech-first approach make it a compelling contender in a sector ripe for disruption. Lockheed, however, isn't out of the fight—its oversold status might attract value-driven investors betting on a rebound.
As the defense industry evolves, this tech-versus-tradition showdown is one stock battle investors can't afford to ignore. 
The question remains: Can Lockheed innovate fast enough to fend off Palantir's charge, or is this the dawn of a new era?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42643303/us-stocks-to-open-higher-as-wall-street-expects-santa-rally-in-shortened-trading-week-microstrategy-palantir-qualcomm-among-stocks-in-focus">US Stocks To Open Higher As Wall Street Expects &#8216;Santa Rally&#8217; In Shortened Trading Week: MicroStrategy, Palantir, Qualcomm Among Stocks In Focus</a></li>
</ul>
Image via Shutterstock

Technicals

Tech

Palantir Vs. Lockheed: A Tech-Fueled Showdown In The $850 Billion Defense Market

Piper Sandler analyst Crispin Love maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Neutral and raises the price target from $168 to $179.

Piper Sandler Maintains Neutral on Blackstone, Raises Price Target to $179

WIIM

NUVB

Nuvation Bio shares are trading higher after the company announced the FDA accepted the New Drug Application for taletrectinib for the treatment of advanced ROS1+ NSCLC.

Anebulo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company" or "Anebulo"), today announced a positive regulatory update and the close of a capital raise.
<ul>
<li>In a Phase 2 proof-of-concept study, Anebulo enrolled 134 adult subjects challenged with oral delta-9-tetrahydrocannabinoil ("THC"), oral selonabant blocked or reversed key CNS effects of THC, establishing the clinical path for intravenous selonabant for a much-needed targeted therapy for rapidly reversing the serious and life-threatening consequences of acute cannabis-induced toxicity in children</li>
<li>Anebulo met with FDA to discuss the development of intravenous selonabant and the initial plan for clinical testing</li>
<li>FDA acknowledged the unmet need for a treatment for children exposed to cannabis toxicity, and proposed a close, ongoing collaboration to efficiently advance the selonabant program for the pediatric indication</li>
<li>Anebulo plans to begin its Phase I SAD study of IV selonabant in healthy adults in 1H25</li>
<li>Anebulo entered into a definitive stock purchase agreement with 22NW, a company controlled by one of its directors, Nantahala Capital and an additional existing investor for the issuance and sale of 15.2 million shares of common stock for gross proceeds of $15 million in a private placement offering priced at-the-market under Nasdaq rules</li>
<li>In exchange for purchasing $10 million of shares of common stock in the private placement, Anebulo intends to modify the Loan and Security Agreement (LSA) that was entered into with 22NW and JFL Capital Management by reducing the maximum loan size to approximately $3 million, which reduces the LSA to just under the securitization threshold, and the removal of any securitization</li>
</ul>

Biotech

General

ANEB

Anebulo Pharmaceuticals Announces FDA Feedback For IV Selonabant To Address Cannabis-Induced Toxicity In Children And Completes $15M Capital Raise; Phase I Study Planned For 1H25

Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) has outperformed the market over the past 20 years by 2.05% on an annualized basis producing an average annual return of 10.3%. Currently, Chubb has a market capitalization of $109.65 billion. 
Buying $1000 In CB: If an investor had bought $1000 of CB stock 20 years ago, it would be worth $7,098.87 today based on a price of $272.01 for CB at the time of writing.
<h3>Chubb's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734963313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Truist Financial analyst Terry Tillman reiterated a Buy rating on nCino (NCNO – Research Report) today. The company's shares opened today at $36.03...

nCino (NCNO) Gets a Buy from Truist Financial

nCino stock slides 12% after soft Q4 guidance, Piper downgrade

nCino's Plunge Was Wholly Justified Despite Exceeding Analysts' Forecasts

Morgan Stanley lowered the firm's price target on nCino (NCNO) to $39 from $41 and keeps an Equal Weight rating on the shares. While the firm antic...

nCino price target lowered to $39 from $41 at Morgan Stanley

Macquarie analyst Robert Trout has maintained their bullish stance on NCNO stock, giving a Buy rating yesterday. Robert Trout's rating is based on ...

nCino's Resilience and Strategic Positioning Suggests Buying Opportunity Amid Market Corrections

Macquarie analyst Robert Trout raised the firm's price target on nCino (NCNO) to $43 from $40 and keeps an Outperform rating on the shares. nCino p...

nCino price target raised to $43 from $40 at Macquarie

Habib Bank Zurich joins hands with nCino to enhance digital services

UBS initiated coverage of nCino (NCNO) with a Buy rating and $44 price target calling the company a "leading" bank IT provider with a "strong growt...

nCino initiated with a Buy at UBS

The latest announcement is out from nCino ( ($NCNO) ). nCino, Inc. has updated the employment agreements for its executive leadership team, includi...

nCino Revises Executive Agreements for Market Alignment

In a regulatory filing, nCino (NCNO) disclosed that its director Jeff Horing sold 4.47M shares of common stock on December 18th in a total transact...

Comments

Ncino

Ncino (NCNO) Options

Ncino (NASDAQ:NCNO) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL